Siweixizangmaoru Decoction Ameliorated Type II Collagen-Induced Arthritis in Rats <i>via</i> Regulating JAK2–STAT3 and NF-κB Signaling Pathway-Reference-Cited by-同舟云学术

Siweixizangmaoru Decoction Ameliorated Type II Collagen-Induced Arthritis in Rats <i>via</i> Regulating JAK2–STAT3 and NF-κB Signaling Pathway

Published:2024-09-13 Issue:9 Volume:47 Page:1511-1524
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Niu Yanfei¹,Feng Qianjing¹,Cui Mingxue¹,Fan Chengde¹,Wang Tong¹,Yuan Ruiying²,Tsering Dikye³,Huang Shan¹,Li Bin¹²^ORCID

Affiliation:

1. Department of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology

2. Department of Pharmacy, College of Medicine, Tibet University

3. Department of Tibetan Medicine, College of Medicine, University of Tibetan Medicine

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/9/47_b24-00362/_pdf

Reference91 articles.

1. 1) Mariani FM, Martelli I, Pistone F, Chericoni E, Puxeddu I, Alunno A. Pathogenesis of rheumatoid arthritis: one year in review 2023. Clin. Exp. Rheumatol., 41, 1725–1734 (2023).

2. 2) Nakano S, Mikami N, Miyawaki M, Yamasaki S, Miyamoto S, Yamada M, Temma T, Nishi Y, Nagaike A, Sakae S, Furusawa T, Kawakami R, Tsuji T, Kohno T, Yoshida Y. Therapeutic strategy for rheumatoid arthritis by induction of myeloid-derived suppressor cells with high suppressive potential. Biol. Pharm. Bull., 45, 1053–1060 (2022).

3. 3) Langbour C, Rene J, Goupille P, Carvajal Alegria G. Efficacy of Janus kinase inhibitors in rheumatoid arthritis. Inflamm. Res., 72, 1121–1132 (2023).

4. 4) Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, Hadano Y, Kayama T, Kurosaka D, Saito M. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int. J. Mol. Sci., 23, 2871 (2022).

5. 5) Buchanan WW, Kean CA, Kean WF, Rainsford KD. Rheumatoid arthritis. Inflammopharmacology, 32, 3–11 (2024).